Neoadjuvant cetuximab, twice-weekly gemcitabine, and intensity-modulated radiotherapy (IMRT) in patients with pancreatic adenocarcinoma

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Molecular Pathogenesis of Head and Neck Cancer

(2010) Jonah D. Klein et al.   CANCER BIOLOGY & THERAPY

Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data

(2010) Monique Maas et al.   LANCET ONCOLOGY

Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement

(2009) Mark P. Callery et al.   ANNALS OF SURGICAL ONCOLOGY

Surgical Results After Preoperative Chemoradiation Therapy for Patients With Pancreatic Cancer

(2009) Sohei Satoi et al.   PANCREAS

Improving Gemcitabine-Mediated Radiosensitization Using Molecularly Targeted Therapy: A Review

(2008) M. A. Morgan et al.   CLINICAL CANCER RESEARCH

The Combination of Epidermal Growth Factor Receptor Inhibitors with Gemcitabine and Radiation in Pancreatic Cancer

(2008) M. A. Morgan et al.   CLINICAL CANCER RESEARCH

Effect of Neoadjuvant Therapy on Local Recurrence after Resection of Pancreatic Adenocarcinoma

(2008) Sarah E. Greer et al.   JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS